ArticleOphthalmology science2023
Geographic Atrophy in Age-Related Macular Degeneration: A Tale of Two Stages.
Article in Ophthalmology science, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Pooled it
- Oral Antioxidant and Lutein/Zeaxanthin Supplements Slow Geographic Atrophy Progression to the Fovea in Age-Related Macular Degeneration.Ophthalmology · 2025Trial
- An Updated Simplified Severity Scale for Age-Related Macular Degeneration Incorporating Reticular Pseudodrusen: Age-Related Eye Disease Study Report Number 42.Ophthalmology · 2024Trial
- What Should Patients With Age-Related Macular Degeneration Eat?American journal of ophthalmology · 2026Review
- Complement Inhibition in Geographic Atrophy: Clinical Evidence for Pegcetacoplan and Avacincaptad Pegol.Cureus · 2026Review
- Phenotyping of Patients with Age-Related Macular Degeneration Using Artificial Intelligence-Driven Biomarker Patterns in OCT.Ophthalmology science · 2026Article
- Geographic Atrophy Progression in Clinical Practice Before and After Pegcetacoplan Treatment.Vision (Basel, Switzerland) · 2025Article
- [Progression assessment for geographic atrophy].Die Ophthalmologie · 2025Review
- Comment on "Phase 2 Study of the Anti-High Temperature Requirement A1 (HtrA1) Fab Galegenimab (FHTR2163) in Geographic Atrophy Secondary to Age-Related Macular Degeneration".American journal of ophthalmology · 2025Article
- Consideration of patient phenotypes in geographic atrophy due to age-related macular degeneration.BMJ open ophthalmology · 2025Review
- Enhanced retinal pigment epithelial cells as a delivery vehicle for retinal disease.Molecular therapy. Methods & clinical development · 2025Article
- Alcohol Consumption and Risk of Age-Related Macular Degeneration and Geographic Atrophy Progression: Age-Related Eye Diseases Study 2 Report 34.Ophthalmology. Retina · 2025Article
- Relationships Between Diet and Geographic Atrophy Progression in the Age-Related Eye Diseases Studies 1 and 2.Nutrients · 2025Article
- Age-related macular degeneration: natural history revisited in geographic atrophy.Eye (London, England) · 2025Review
- Informing Endpoints for Clinical Trials of Geographic Atrophy.Annual review of vision science · 2024Review
- Expert Consensus on Geographic Atrophy in the EU: A Call for Urgent Policy Action.Ophthalmology and therapy · 2024Article
- Critical Dependence on Area in Relationship between ARMS2/HTRA1 Genotype and Faster Geographic Atrophy Enlargement: Age-Related Eye Disease Study 2 Report Number 33.Ophthalmology · 2024Article
- Geographic atrophy: pathophysiology and current therapeutic strategies.Frontiers in ophthalmology · 2023Review
- Geographic atrophy: Understanding the relationship between structure and function.Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)Review
- Investigating Macular Tissue Integrity Index as a Novel Biomarker in Geographic Atrophy.Ophthalmology scienceArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To examine disease progression in age-related macular degeneration (AMD) at 2 distinct stages, progression to geographic atrophy (GA) versus GA expansion, by comparison of the risk and protective factors at each stage. Design: Perspective. Subjects: Individuals at risk of GA or with GA. Main Outcome Measures: Progression to GA and GA expansion rate. Methods: Critical synthesis of the literature on risk and protective factors, both environmental and genetic, for progression to GA versus GA expansion in AMD. Results: Comparison of the risk and protective factors demonstrates partially overlapping but partially distinct risk and protective factors for progression to GA versus GA expansion. Some factors are shared (i.e., operating in the same direction at both stages), others are not shared, and others seem to operate in different directions at each stage. Risk variants at Conclusions: Analysis of the risk and protective factors for progression to GA and GA expansion demonstrates partially overlapping but partially distinct elements at each stage: some are shared, some are relevant to 1 stage only, and some even seem active in opposite directions at each stage. Aside from Financial Disclosures: Proprietary or commercial disclosure may be found after the references.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.